IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1750 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (427 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   References
   Article Tables

 Article Access Statistics
    Viewed88    
    Printed0    
    Emailed0    
    PDF Downloaded11    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR
Year : 2021  |  Volume : 53  |  Issue : 5  |  Page : 417-419
 

Rhino-orbital-cerebral mucormycosis in COVID-19 patients – Taming the black evil with pharmacological weapons


1 Consultant Cataract, Pediatric Ophthalmology and Strabismus Services, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Puducherry, India
2 Consultant Cataract, Cornea and Refractive Services, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Puducherry, India

Date of Submission17-Jul-2021
Date of Decision28-Aug-2021
Date of Acceptance28-Aug-2021
Date of Web Publication24-Nov-2021

Correspondence Address:
Dr. Bharat Gurnani
Consultant Cataract, Cornea and Refractive Services, Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Puducherry-605 007
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijp.ijp_392_21

Rights and Permissions



How to cite this article:
Kaur K, Gurnani B. Rhino-orbital-cerebral mucormycosis in COVID-19 patients – Taming the black evil with pharmacological weapons. Indian J Pharmacol 2021;53:417-9

How to cite this URL:
Kaur K, Gurnani B. Rhino-orbital-cerebral mucormycosis in COVID-19 patients – Taming the black evil with pharmacological weapons. Indian J Pharmacol [serial online] 2021 [cited 2021 Dec 8];53:417-9. Available from: https://www.ijp-online.com/text.asp?2021/53/5/417/331078






Sir,

The global pandemic caused by COVID-19 virus has infected over 130 million across the globe, resulting in more than 2.8 million deaths on the day of writing this letter. At present, India is fighting against the second wave of COVID-19, which has proven to be more dangerous, spreading faster, and claiming more lives. A wide spectrum of secondary fungal and bacterial co-infections are being reported.[1] These may be associated with preexisting morbidities such as uncontrolled diabetes, lung pathologies, or may result from hospital-induced ventilator-associated pneumonia. There is another fungal pandemic in the form of fatal mucormycosis building up in our country. There is an urgent need to combat this deadly infection to prevent disastrous sequelae. This letter is aimed at giving useful insights into stages of mucormycosis, clinical profile, and various pharmacological options available to combat this emergency during the pandemic.

India is the diabetic capital of the world having 77 million diabetic patients (8.9% adults) constituting a major risk factor for mucormycosis. The health experts have already raised concerns about the possibility of 2500 mucormycosis cases per day in India. The major predisposing factors include diabetes mellitus, corticosteroids overuse, immunodeficiency diseases, malignancies or immunosuppressive drugs, COVID-19 infection, patients on remdesivir, tocilizumab, and iron overload in the body. Rawson et al.[2] in their review found that 8% (62/806) of the patients during the hospital stay had developed secondary fungal or bacterial infections.[2] The patients with secondary fungal infections are at increased risk of developing widespread pulmonary pathology and alveoli-interstitial lung disease. These fatal and invasive fungal infections are probably due to specific pathophysiological manifestations of the COVID-19 virus. Moreover, the immune dysregulation induced by COVID-19 virus reduces the T-lymphocytes number including CD4+ T cells and CD8+ T cells significantly. This results in altered innate immunity. A recent study highlighted 26.7% incidence of invasive fungal infections and 53% mortality of COVID-19-admitted patients.

Mucormycosis can be categorized into four stages. Stage 1 (nasal mucosa involvement) is characterized by nasal discharge, stuffiness, epistaxis, and foul smell. Stage 2 (paranasal sinuses involvement) manifestations include dental and facial pain, edema, and sinus tenderness. Stage 3 (orbital and ocular involvement) manifestations include ptosis, proptosis, diplopia, and cranial nerve involvement. Stage 4 (neurological involvement) is characterized by higher mental function involvement, seizures, paralysis, and cavernous sinus thrombosis. The laboratory diagnosis is based on smearing on 10% KOH mount, fluorescence on calcofluor white, and culture of mucor hyphae on sabouraud dextrose agar, potato dextrose agar, and brain hear infusion broth. Imaging options are vital to rule out central nervous system involvement which includes contrast enhance magnetic resonance imaging and computed tomography scan in which magnetic resonance imaging takes an upper hand owing to its high sensitivity and specificity for soft tissue delineation. The management is dependent on prompt clinical and laboratory diagnosis, meticulous risk stratification, and targeted and appropriate drug therapy with multiple aggressive interventions to safeguard life. The various pharmacological drugs available for the treatment can be categorized as liposomal amphotericin B (LAMB) (lipid formulation), posaconazole, and isavuconzole. Recently, novel pharmacotherapeutic drugs have shown promise in the management of mucormycosis with other comorbidities. These include combination therapy in the form of amphotericin B (AMB) + echinocandins, AMB + triazole, polyene and posaconazole, anti-retroviral therapy + AMB (HIV), AMB + hematopoietic growth factors, white cell transfusion graft-versus-host-disease, AMB + deferasirox (synergistic action), AMB + hyperbaric oxygen (synergistic action), and AMB + interferon-γ + Nivolumab (inhibit mucormycosis) [Table 1]. In uncontrolled mucormycosis, i.e., usually Stage 3 and above, the management rests on amphotericin-assisted sinus irrigation, surgical debridement, and orbital exenteration. If the patient is systemically unfit to undergo surgical intervention, LAMB is the gold standard with aggressive metabolic control.
Table 1: Various pharmacological management options for mucormycosis[3]

Click here to view


Hirabayashi et al.[4] also reported that AMB deoxycholate retrobulbar injections, systemic intravenous (IV) antifungals, and debridement of the sinuses endoscopically act as a very good treatment option for orbital mucormycosis. Joos and Patel[5] in their case report proved that when the orbital cavity was irrigated daily with AMB, it resulted in effective infection control and also avoided the need for orbital exenteration in cases with extensive nasal and orbital involvement. COVID-19-induced immunosuppression, corticosteroids use, and mechanical ventilation along with uncontrolled DM have ignited another flame of the mucor pandemic. This had added to not only mortality but also to the economic burden for poor socioeconomic strata in India. IV LAMB is a costly drug and a single treatment may cost around an average of 4–8 lakhs. Ophthalmologists, ear, nose, and throat specialists, neurologists, and even pharmacologists play a huge role in the early diagnosis of mucormycosis associated with COVID-19. We have to search for cost-effective drug alternatives if the mucormycosis pandemic continues in the near future. We believe that pharmacological research and multidisciplinary collaboration have a huge role to play in combating this deadly infection of mucor in a viral land.

Acknowledgments

The authors would like to thank Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Pondicherry.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): A global pandemic and treatment strategies. Int J Antimicrob Agents 2020;56:106054.  Back to cited text no. 1
    
2.
Rawson TM, Moore LS, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal coinfection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020;71:2459-68.  Back to cited text no. 2
    
3.
Sipsas NV, Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP. Therapy of mucormycosis. J Fungi (Basel) 2018;4:E90.  Back to cited text no. 3
    
4.
Hirabayashi KE, Kalin-Hajdu E, Brodie FL, Kersten RC, Russell MS, Vagefi MR. Retrobulbar injection of amphotericin B for orbital mucormycosis. Ophthalmic Plast Reconstr Surg 2017;33:e94-7.  Back to cited text no. 4
    
5.
Joos ZP, Patel BC. Intraorbital irrigation of amphotericin B in the treatment of rhino-orbital mucormycosis. Ophthalmic Plast Reconstr Surg 2017;33:e13-6.  Back to cited text no. 5
    



 
 
    Tables

  [Table 1]



 

Top
Print this article  Email this article
 

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow